MarketBeat
19 Nov 2026, 03:12 UTC · 16h ago
Exelixis Eyes Q1 Zanza Data as It Plans Beyond CABO
Impact · against what's priced in
The upcoming Q1 2027 data for Zanza in non-clear cell renal cell carcinoma provides a concrete near-term catalyst for Exelixis, though its impact is limited by the small size of the indication. Other strategic points, such as R&D spending and the goal of replacing the CABO franchise, are already reflected in the current premium valuation.
- EXEL+0.20
Not in the price yet
- The price assumes
The full financial upside of zanzalintinib across renal cell carcinoma and lung cancer
The market is not currently paying for Zanza's full upside in renal cell carcinoma; the confirmation of top-line results for the non-clear cell RCC study in Q1 2027 provides a specific timeline for the first readout of this expansion.
What EXEL's price assumes · Sep 4





